Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

被引：0
|
作者：
Tiacci, Enrico [1 ,2 ]
De Carolis, Luca [1 ,2 ]
Capponi, Monia [1 ,2 ]
Falcinelli, Flavio [1 ,2 ]
Zaja, Francesco [3 ,4 ]
Pulsoni, Alessandro [5 ]
Simonetti, Edoardo [1 ,2 ]
Montechiarello, Elisa [6 ]
Romano, Alessandra [7 ]
Olivieri, Jacopo [8 ]
Mancini, Alessandro [1 ,2 ]
D'Elia, Gianna Maria [9 ,10 ]
Foa, Robin [9 ,10 ]
Frezzato, Maurizio [11 ]
Falini, Brunangelo [2 ]
机构：
[1] Univ & Hosp Perugia, Inst Hematol, Perugia, Italy
[2] Univ & Hosp Perugia, Ctr Hematooncol Res, Perugia, Italy
[3] Univ Trieste, DSM, Trieste, Italy
[4] Azienda Sanit Univ Giuliano Isontina, UCO Ematologia, Trieste, Italy
[5] Univ Sapienza, SM Goretti Hosp, Hematol, Latina, Italy
[6] Hosp Reggio Calabria, Hematol, Reggio Di Calabria, Italy
[7] Univ & Hosp Catania, Hematol, Catania, Italy
[8] Azienda Sanit Univ Integrata Udine, Ctr Trapianti & Terapie Cellulari Carlo Melzi, Clin Ematol, Udine, Italy
[9] Univ Sapienza, Hematol, Rome, Italy
[10] Hosp Umberto I, Rome, Italy
[11] Hosp Vicenza, Hematol, Vicenza, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [43] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Agrawal, Vaibhav
    Croslin, Cindy
    Beltran, Asuscena L.
    Zhang, Jianying
    Palmer, Joycelynne
    Quy Huynh-Tran
    Hernandez, Rochelle
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Ali, Haris
    Stein, Anthony S.
    Budde, Elizabeth L.
    Al Malki, Monzr M.
    Marcucci, Guido
    BLOOD, 2022, 140 : 6235 - 6236
  • [44] Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
    Herrera, Alex F.
    Ansell, Stephen M.
    Zinzani, Pier Luigi
    Radford, John
    Maddocks, Kami J.
    Pinto, Antonio
    Collins, Graham P.
    Bachanova, Veronika
    Bartlett, Nancy L.
    Bence-Bruckler, Isabelle
    Hamadani, Mehdi
    Kline, Justin
    Mayer, Jiri
    Savage, Kerry J.
    Advani, Ranjana H.
    Caimi, Paolo F.
    Casasnovas, Rene-Olivier
    Feldman, Tatyana A.
    Hess, Brian T.
    Bastos-Oreiro, Mariana
    Iyengar, Sunil
    Szomor, Arpad
    Townsend, William
    Andre, Marc
    Dyczkowski, Jerzy
    Eisen, Sandy
    Urban, Andrzej
    Pantano, Serafino
    Cruz, Hans G.
    Wang, Luqiang
    Negievich, Yanina
    Wuerthner, Jens
    Carlo-Stella, Carmelo
    BLOOD, 2022, 140 : 3673 - 3677
  • [45] Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
    Panayiotidis, Panayiotis
    Tumyan, Gayane
    Thieblemont, Catherine
    Ptushkin, Vadim V.
    Niebla, Ana Marin
    Garcia-Sanz, Ramon
    Zaritskey, Andrey
    Le Gouill, Steven
    Buske, Christian
    Van Hoef, Marlies
    Perretti, Thomas
    Tomiczek, Monique S.
    Stathis, Anastasios
    BLOOD, 2020, 136
  • [46] Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
    Maude, Shannon L.
    Pulsipher, Michael A.
    Boyer, Michael W.
    Grupp, Stephan A.
    Davies, Stella M.
    Phillips, Christine L.
    Verneris, Michael R.
    August, Keith J.
    Schlis, Krysta
    Driscoll, Timothy A.
    Mody, Rajen
    Capitini, Christian M.
    June, Carl H.
    Levine, Bruce L.
    Wood, Patricia A.
    Yi, Lan
    Levine, John E.
    BLOOD, 2016, 128 (22)
  • [47] Atezolizumab plus obinutuzumab plus venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.
    Herbaux, Charles
    Ghesquieres, Herve
    Bouabdallah, Reda
    Guidez, Stephanie
    Gyan, Emmanuel
    Gressin, Remi
    Morineau, Nadine
    Ysebaert, Loic
    Le Gouill, Steven
    Laurent, Camille
    Tilly, Herve
    Houot, Roch
    Damaj, Gandhi
    Sibon, David
    Feugier, Pierre
    Thieblemont, Catherine
    Haioun, Corinne
    Tarte, Karine
    Morschhauser, Franck
    Cartron, Guillaume
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) plus regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC)
    Fogelman, David R.
    Bendell, Johanna C.
    Cubillo, Antonio
    Alfonso, Pilar Garcia
    Miron, Maria Luisa Limon
    Nemunaitis, John J.
    Flora, Daniel Blake
    Borg, Christophe
    Mineur, Laurent
    Vieitez, Jose M.
    Cohn, Allen Lee
    Saylors, Gene Brian
    Assad, Albert
    Switzky, Julie C.
    O'Neill, Peter
    Zhou, Li
    Kochenderfer, Mark D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [49] Naxitamab Treatment of Refractory/Relapsed High-Risk Neuroblastoma (R/R HR NB); Subgroup Analysis of Updated Interim Efficacy and Safety Data for The Registrational Phase II Trial
    Mora, J.
    Bear, M.
    Chan, G. Chi-Fung
    Morgenstern, D.
    Nysom, K.
    Tornoe, K.
    Losic, N.
    Kushner, B.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S85 - S85
  • [50] A multicenter phase I/II trial evaluating the safety and efficacy of Lenalidomide [Revlimida (R), CC-5013] in combination with doxorubicin and dexamethasone (RAD) in patients with relapsed or refractory multiple myeloma.
    Gerecke, C
    Knop, S
    Topp, MS
    Kotkiewitz, S
    Gollasch, H
    Liebisch, P
    Hess, G
    Watters, K
    Einsele, H
    Bargou, RC
    BLOOD, 2005, 106 (11) : 367B - 367B
12345